Bicycle Therapeutics Plc ADR’s recently made public that its CHIEF EXECUTIVE OFFICER Lee Kevin unloaded Company’s shares for reported $71499.0 on Oct 03 ’24. In the deal valued at $22.26 per share,3,212 shares were sold. As a result of this transaction, Lee Kevin now holds 380,864 shares worth roughly $10.08 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Hannay Michael Charles Ferguso sold 247 shares, generating $5,498 in total proceeds. Upon selling the shares at $22.26, the CHIEF PROD & SUPPLY CHAIN OFF now owns 22,398 shares.
Before that, Skynner Michael sold 972 shares. Bicycle Therapeutics Plc ADR shares valued at $21,637 were divested by the CHIEF TECHNOLOGY OFFICER at a price of $22.26 per share. As a result of the transaction, Skynner Michael now holds 92,945 shares, worth roughly $2.46 million.
RBC Capital Mkts initiated its Bicycle Therapeutics Plc ADR [BCYC] rating to an Outperform in a research note published on September 06, 2024; the price target was $35. A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who decreased its forecast for the stock in early August from “a Buy” to “a Neutral”. B. Riley Securities also remained covering BCYC and has increased its forecast on September 11, 2023 with a “Buy” recommendation from previously “Neutral” rating. Cowen started covering the stock on August 31, 2022. It rated BCYC as “an Outperform”.
Price Performance Review of BCYC
On Friday, Bicycle Therapeutics Plc ADR [NASDAQ:BCYC] saw its stock jump 5.67% to $26.46. Over the last five days, the stock has gained 12.12%. Bicycle Therapeutics Plc ADR shares have risen nearly 46.35% since the year began. Nevertheless, the stocks have risen 26.18% over the past one year. While a 52-week high of $28.20 was reached on 09/12/24, a 52-week low of $12.54 was recorded on 01/05/24. SMA at 50 days reached $23.46, while 200 days put it at $22.32.
Levels Of Support And Resistance For BCYC Stock
The 24-hour chart illustrates a support level at 25.02, which if violated will result in even more drops to 23.58. On the upside, there is a resistance level at 27.63. A further resistance level may holdings at 28.80. The Relative Strength Index (RSI) on the 14-day chart is 66.21, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.78, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 16.04%. Stochastics %K at 77.49% indicates the stock is a holding.
How much short interest is there in Bicycle Therapeutics Plc ADR?
A steep rise in short interest was recorded in Bicycle Therapeutics Plc ADR stocks on 2024-09-30, growing by 0.55 million shares to a total of 2.65 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-30 was 2.1 million shares. There was a rise of 20.6%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 28, 2022 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $30 price target.
